Details for New Drug Application (NDA): 203053
✉ Email this page to a colleague
The generic ingredient in EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE is efavirenz; emtricitabine; tenofovir disoproxil fumarate. There are twenty-six drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the efavirenz; emtricitabine; tenofovir disoproxil fumarate profile page.
Summary for 203053
Tradename: | EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE |
Applicant: | Hetero Labs Ltd V |
Ingredient: | efavirenz; emtricitabine; tenofovir disoproxil fumarate |
Patents: | 0 |
Suppliers and Packaging for NDA: 203053
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE | efavirenz; emtricitabine; tenofovir disoproxil fumarate | TABLET;ORAL | 203053 | ANDA | Camber Pharmaceuticals, Inc. | 31722-736 | 31722-736-30 | 30 TABLET, FILM COATED in 1 BOTTLE (31722-736-30) |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 600MG;200MG;300MG | ||||
Approval Date: | Jan 24, 2022 | TE: | AB | RLD: | No |
Complete Access Available with Subscription